$PSTV News

Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid Assay

Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS Oncology

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Plus Therapeutics Q1 EPS $(1.05) Misses $(0.85) Estimate, Sales $1.028M Beat $974.000K Estimate

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Plus Therapeutics Presents Plenary Session Reviewing Key Clinical And Translational Data, Including Phase 1 ReSPECT-LM Trial Of REYOBIQ At 2026 AANS Annual Scientific Meeting

OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Plus Therapeutics Subsidiary Gets Enrolled In Medicare Program, Receives Provider Transaction Access Number From Centers For Medicare & Medicaid Services

Plus Therapeutics' Subsidiary CNside Diagnostics Announces New Payer Coverage Agreement With Blue Shield Of California, Effective April 2026, Providing Reimbursement For Its CNside Cerebrospinal Fluid Tumor Cell Enumeration Assay For Metastatic Central Nervous System Cancer Patients

Plus Therapeutics' Subsidiary CNside Diagnostics Announces New Payer Coverage Agreement With Blue Shield Of California, Effective April 2026, Providing Reimbursement For Its CNside Cerebrospinal Fluid Tumor Cell Enumeration Assay For Metastatic Central Nervous System Cancer Patients

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Plus Therapeutics Regains Nasdaq Compliance

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Why Is Plus Therapeutics Stock Gaining Friday?

Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $65